Leqembi

Leqembi is the brand name for lecanemab, an intravenous medication approved for the treatment of early Alzheimer's disease. It is a monoclonal antibody designed to target and remove amyloid plaques, which are abnormal protein deposits that accumulate in the brain and are believed to contribute to the progression of Alzheimer's. Leqembi works by binding to these amyloid plaques, facilitating their clearance by the immune system.

The medication is administered by a healthcare professional every two weeks. Clinical trials have shown that Leqembi can slow cognitive and functional decline in individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, it does not cure Alzheimer's disease and does not reverse existing damage.

Like all medications, Leqembi carries potential risks and side effects. The most significant concern is amyloid-related imaging abnormalities (ARIA), which can manifest as swelling or bleeding in the brain. ARIA is often asymptomatic, but in some cases, it can lead to serious neurological symptoms. Other potential side effects include infusion-related reactions, headache, and dizziness.

The decision to use Leqembi should be made in consultation with a healthcare provider who can assess the individual's specific condition, medical history, and potential benefits and risks. Regular monitoring through MRI scans is recommended to detect and manage ARIA. Leqembi represents a significant development in Alzheimer's treatment, offering a new therapeutic approach to target the underlying pathology of the disease.